Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of RAY1225 Injection in Healthy Participants
NCT07827027Phase 1Not yet recruiting
- Sponsor
- Raynovent Biotech
- Start
- Sep 2026
- Primary completion
- Nov 2026
01
Overview
Phase 1, randomised, open-label trial of RAY1225 in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Raynovent Biotech. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to T at Day 43 and Maximum Concentration at Day 43. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
RAY1225
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07827027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827027.